These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
739 related articles for article (PubMed ID: 25975820)
1. Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines. Cursons J; Leuchowius KJ; Waltham M; Tomaskovic-Crook E; Foroutan M; Bracken CP; Redfern A; Crampin EJ; Street I; Davis MJ; Thompson EW Cell Commun Signal; 2015 May; 13():26. PubMed ID: 25975820 [TBL] [Abstract][Full Text] [Related]
2. Taiwan cobra cardiotoxin III suppresses EGF/EGFR-mediated epithelial-to-mesenchymal transition and invasion of human breast cancer MDA-MB-231 cells. Tsai PC; Fu YS; Chang LS; Lin SR Toxicon; 2016 Mar; 111():108-20. PubMed ID: 26774845 [TBL] [Abstract][Full Text] [Related]
3. Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells. Bocca C; Bozzo F; Cannito S; Parola M; Miglietta A Mol Carcinog; 2012 Oct; 51(10):783-95. PubMed ID: 21882253 [TBL] [Abstract][Full Text] [Related]
4. Epithelial to mesenchymal transition is associated with rapamycin resistance. Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619 [TBL] [Abstract][Full Text] [Related]
5. Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control. Grassi ML; Palma CS; Thomé CH; Lanfredi GP; Poersch A; Faça VM J Proteomics; 2017 Jan; 151():2-11. PubMed ID: 27394697 [TBL] [Abstract][Full Text] [Related]
6. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells. Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225 [TBL] [Abstract][Full Text] [Related]
7. Janus kinases and Src family kinases in the regulation of EGF-induced vimentin expression in MDA-MB-468 breast cancer cells. Stewart TA; Azimi I; Brooks AJ; Thompson EW; Roberts-Thomson SJ; Monteith GR Int J Biochem Cell Biol; 2016 Jul; 76():64-74. PubMed ID: 27163529 [TBL] [Abstract][Full Text] [Related]
8. The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line. Satram-Maharaj T; Nyarko JN; Kuski K; Fehr K; Pennington PR; Truitt L; Freywald A; Lukong KE; Anderson DH; Mousseau DD Cell Signal; 2014 Dec; 26(12):2621-32. PubMed ID: 25152370 [TBL] [Abstract][Full Text] [Related]
9. Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation. Tomei P; Masola V; Granata S; Bellin G; Carratù P; Ficial M; Ventura VA; Onisto M; Resta O; Gambaro G; Chilosi M; Lupo A; Zaza G J Nephrol; 2016 Dec; 29(6):881-891. PubMed ID: 27026415 [TBL] [Abstract][Full Text] [Related]
10. Specific N-glycan alterations are coupled in epithelial-mesenchymal transition induced by EGF in GE11 epithelial cells. Xu Q; Qu C; Wang W; Gu J; Du Y; Song L Cell Biol Int; 2017 Feb; 41(2):124-133. PubMed ID: 27888538 [TBL] [Abstract][Full Text] [Related]
11. TRPC1 is a differential regulator of hypoxia-mediated events and Akt signalling in PTEN-deficient breast cancer cells. Azimi I; Milevskiy MJG; Kaemmerer E; Turner D; Yapa KTDS; Brown MA; Thompson EW; Roberts-Thomson SJ; Monteith GR J Cell Sci; 2017 Jul; 130(14):2292-2305. PubMed ID: 28559303 [TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023 [TBL] [Abstract][Full Text] [Related]
13. Livin promotes progression of breast cancer through induction of epithelial-mesenchymal transition and activation of AKT signaling. Li F; Yin X; Luo X; Li HY; Su X; Wang XY; Chen L; Zheng K; Ren GS Cell Signal; 2013 Jun; 25(6):1413-22. PubMed ID: 23524337 [TBL] [Abstract][Full Text] [Related]
14. Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells. Hugo HJ; Pereira L; Suryadinata R; Drabsch Y; Gonda TJ; Gunasinghe NP; Pinto C; Soo ET; van Denderen BJ; Hill P; Ramsay RG; Sarcevic B; Newgreen DF; Thompson EW Breast Cancer Res; 2013 Nov; 15(6):R113. PubMed ID: 24283570 [TBL] [Abstract][Full Text] [Related]
15. Ascofuranone inhibits epidermal growth factor-induced cell migration by blocking epithelial-mesenchymal transition in lung cancer cells. Kim HW; Jeong YJ; Hwang SK; Park YY; Choi YH; Kim CH; Magae J; Chang YC Eur J Pharmacol; 2020 Aug; 880():173199. PubMed ID: 32439259 [TBL] [Abstract][Full Text] [Related]
16. Novel anti-cancer agent myrtucommulone-A and thymoquinone abrogate epithelial-mesenchymal transition in cancer cells mainly through the inhibition of PI3K/AKT signalling axis. Iskender B; Izgi K; Canatan H Mol Cell Biochem; 2016 May; 416(1-2):71-84. PubMed ID: 27032769 [TBL] [Abstract][Full Text] [Related]
17. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401 [TBL] [Abstract][Full Text] [Related]
18. Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Davis FM; Azimi I; Faville RA; Peters AA; Jalink K; Putney JW; Goodhill GJ; Thompson EW; Roberts-Thomson SJ; Monteith GR Oncogene; 2014 May; 33(18):2307-16. PubMed ID: 23686305 [TBL] [Abstract][Full Text] [Related]
19. Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. Liu J; Chen X; Ward T; Mao Y; Bockhorn J; Liu X; Wang G; Pegram M; Shen K Int J Biochem Cell Biol; 2016 Feb; 71():12-23. PubMed ID: 26643609 [TBL] [Abstract][Full Text] [Related]
20. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition. Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]